Sarepta Therapeutics Profit Margin

The latest profit margin for SRPT is -13.48% as of June 2026. That compares with -2.34% in the prior-year period — down 477.1% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Sarepta Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SRPT's profit margin moved from -2.34% to -13.48% — a 477.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sarepta Therapeutics's valuation or profitability profile.

Against Healthcare companies, SRPT currently prints -13.48% for profit margin, while the sector average sits near 13.89%. That is roughly 197.0% below the sector mean. Large gaps often invite a closer look at Sarepta Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Sarepta Therapeutics converts resources into returns. At -13.48%, SRPT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2.34% in the prior-year period — down 477.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SRPT's profit margin (-13.48%), review year-over-year change from -2.34%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.